IL6 and COVID-19: Deep vein thrombosis prophylaxis was administered in 83.9% of patients in COVID-19–dedicated hospital compared with 56.9% of those in other hospitals (P < .001), high-dose corticosteroids in 56.1% vs 22.2% (P < .001), remdesivir in 61.5% vs 44.5% (P < .001), and the anti-IL-6 antibody tocilizumab in 7.9% of vs 2.0% (P < .001) (eTable 3 in the Supplement).